Oligoclonal T cell expansions in patients with Behçet's disease.


Direskeneli H., Eksioglu-Demiralp E., Kibaroglu A., Yavuz S., Ergun T., Akoglu T.

Clinical and experimental immunology, cilt.117, sa.1, ss.166-70, 1999 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 117 Sayı: 1
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1046/j.1365-2249.1999.00931.x
  • Dergi Adı: Clinical and experimental immunology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.166-70
  • Anahtar Kelimeler: Behcet's disease, T cell receptor, V beta usage, SHOCK PROTEIN-PEPTIDES, GENE USAGE, RECEPTOR, IMMUNOHISTOLOGY, SUPERANTIGENS, MYCOBACTERIAL, PATHOGENESIS, EXPRESSION, EPITOPE, HSP
  • Marmara Üniversitesi Adresli: Evet

Özet

Behcet's disease (BD) is a multisystem disorder with oral and genital ulcers, mucocutaneous, ocular, joint, vascular and central nervous system involvement. In this study, the peripheral T cell repertoire was analysed in patients with BD with MoAbs against T cell receptor (TCR) V beta gene products in CD4(+) and CD8(+) T cell compartments, and these were compared with rheumatoid arthritis (RA) patients and healthy controls (HC). In the CD4(+) T cell compartment, oligoclonal TCR V beta expression was observed in 56% of BD (10/18), 71% of RA (5/7) patients and 21% (3/14) of HC. In the CD8(+) T cell group 50% of BD (9/18), 57% of RA patients and 28% of HC (4/14) had an oligoclonal TCR repertoire. An increase of TCR V beta 5.1 subset was observed in five BD patients among CD8(+) T cells. Other elevations of TCR V beta subsets were heterogeneously distributed with one to three different V beta subsets. Our results suggest an antigen-driven oligoclonal increase of T cells in BD. There was no overall increase in any V beta group to suggest a superantigen effect. Analysis of the responsible antigens causing the increase in T cell subsets may give insights into the aetiopathogenesis of BD and immunomodulation of these T cells may lead to new treatments.